What is ResMed's D&A?

ResMed (RMD) reported D&A of $7.85M in Q1 2026.

How has ResMed's D&A changed year-over-year?

ResMed's D&A increased by 5.5% year-over-year, from $7.44M to $7.85M.

What is the long-term trend for ResMed's D&A?

Over 3 years (2022 to 2025), ResMed's D&A has grown at a -30.9% compound annual growth rate (CAGR), from $97.25M to $32.12M.

Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

ResMed RMD D&A

D&A at other companies

Viemed Healthcare, Inc.VMD

$388K+11.5%

MedtronicMDT

$716M-14.8%

InsmedINSM

$2.08M+64.8%

SavaraSVRA

$24K-20.0%

NovantaNOVT

$5.77M+4.0%

Baxter InternationalBAX

$237M-4.0%

Segments

By segment

See full

Sleep And Breathing Health$36.86M+61.5%

Residential Care Software$2.75M+22.3%

By product

See full

Residential Care Software$6.43M+2.7%

Sleep And Breathing Health$1.42M+20.2%

Other financials

Income statement

See full

Revenue$1.4B+10.8%

Gross profit$891.0M+16.3%

Operating income$499.8M+17.3%

Net income$398.7M+9.2%

EPS (diluted)$2.74+10.5%

Balance sheet

See full

Cash & equivalents$1.7B+78.0%

Total debt$1.1B+29.8%

Total equity$6.5B+17.1%

Total assets$8.8B+16.1%

Cash flow

See full

Operating cash flow$554.1M-4.2%

CapEx$33.7M+61.8%

Free cash flow$520.5M-6.7%

Valuation

See full

Market cap$29.05B-22.6%

Enterprise value$28.5B-23.3%

P/E19.1×-7.7×

P/S5.3×-2.0×

Profitability

See full

Gross margin61.6%+2.8pp

Operating margin34.2%+2.1pp

Net margin27.4%+1.3pp

FCF margin31.7%+0.4pp

Returns & leverage

See full

Return on equity25.2%-0.6pp

Debt / equity0.2×0.0×

Current ratio3×-0.4×

Where this comes from

Reported directly by ResMed in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: ResMed’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about ResMed's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ResMed's D&A?: ResMed (RMD) reported D&A of $7.85M in Q1 2026.
How has ResMed's D&A changed year-over-year?: ResMed's D&A increased by 5.5% year-over-year, from $7.44M to $7.85M.
What is the long-term trend for ResMed's D&A?: Over 3 years (2022 to 2025), ResMed's D&A has grown at a -30.9% compound annual growth rate (CAGR), from $97.25M to $32.12M.
What does D&A mean?: Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.